Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

XTAMPZA ER Drug Profile

« Back to Dashboard

Which patents cover Xtampza Er, and what substitute generic drugs are available?

Xtampza Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has thirteen patent family members in five countries.

The generic ingredient in XTAMPZA ER is oxycodone. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. There are seven tentative approvals for this compound. Additional details are available on the oxycodone profile page.

Summary for Tradename: XTAMPZA ER

Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list14
Patent Applications: see list8,971
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XTAMPZA ER at DailyMed

Pharmacology for Tradename: XTAMPZA ER

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Collegium Pharm Inc
XTAMPZA ER
oxycodone
CAPSULE, EXTENDED RELEASE;ORAL208090-005Apr 26, 2016RXYesYes8,449,909► SubscribeY ► Subscribe
Collegium Pharm Inc
XTAMPZA ER
oxycodone
CAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo9,044,398► SubscribeY ► Subscribe
Collegium Pharm Inc
XTAMPZA ER
oxycodone
CAPSULE, EXTENDED RELEASE;ORAL208090-005Apr 26, 2016RXYesYes► Subscribe► Subscribe
Collegium Pharm Inc
XTAMPZA ER
oxycodone
CAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo8,758,813► Subscribe ► Subscribe
Collegium Pharm Inc
XTAMPZA ER
oxycodone
CAPSULE, EXTENDED RELEASE;ORAL208090-004Apr 26, 2016RXYesNo9,248,195► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XTAMPZA ER

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005123039► Subscribe
Canada2491572► Subscribe
Japan2006500426► Subscribe
Australia2003247876► Subscribe
Japan4694207► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XTAMPZA ER

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc